Price$1.34-0.13 (-8.50%)
2026-02-272026-06-02
News · 26 weeks20-60%
2025-12-072026-05-31
Mix1090d
- SEC Filings5(50%)
- Other4(40%)
- Analyst1(10%)
Latest news
25 items- PRMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001 (ti
- SECSEC Form 10-Q filed by Medicinova Inc10-Q - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form DEFA14A filed by Medicinova IncDEFA14A - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form DEF 14A filed by Medicinova IncDEF 14A - MEDICINOVA INC (0001226616) (Filer)
- PRNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationLA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer‑reviewed journal "Cancer Research" (March 2026), demonstrates pharmacological modulation of this pathway using the brain‑penetrant small molecule ibud
- SECSEC Form PRER14A filed by Medicinova IncPRER14A - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form PRE 14A filed by Medicinova IncPRE 14A - MEDICINOVA INC (0001226616) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on MediciNova with a new price targetH.C. Wainwright initiated coverage of MediciNova with a rating of Buy and set a new price target of $10.00
- PRMediciNova to Participate at the 38th Annual ROTH ConferenceLA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer will participate at the 38th Annual ROTH Conference. The conference is being held on March 22 – 24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. Drs. Iwaki and Crean will host one-on-one and small group meetings with investors and provide company updates. Investors interested in arranging a meeting should contact their representatives
- SECSEC Form 10-K filed by Medicinova Inc10-K - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsLA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). Dr. Yuichi Iwaki, President and CEO of MediciNova, commented: "Achieving 100 enrolled patients in the N
- INSIDERSEC Form 4 filed by Chief Medical Officer Matsuda Kazuko4 - MEDICINOVA INC (0001226616) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Iwaki Yuichi4 - MEDICINOVA INC (0001226616) (Issuer)
- PR2026 New Year's Greetings from the CEOLA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. Dear Fellow Shareholders, The year 2025 was marked by global uncertainty, with accelerating inflation, evolving U.S. trade policies under the new administration, and persistent geopolitical risks. Despite these challenges, MediciNova achieved significant milestones, including completion of patient enrollment in three clinical trials and the launch of a large-
- SECSEC Form 424B5 filed by Medicinova Inc424B5 - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyLA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Haryana Dhillon, is evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. A total
- SECSEC Form EFFECT filed by Medicinova IncEFFECT - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MNDLA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients' basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND, held December 5–7, 2025, in San Diego, California, USA. The poster presentation, titled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Basic Characteristics" (Reference # CTL-21),
- SECSEC Form S-3 filed by Medicinova IncS-3 - MEDICINOVA INC (0001226616) (Filer)
- PRMessage from the CEO to MediciNova ShareholdersLA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provide additional perspective on why this research represents a significant milestone for MediciNova and our MN-001 program. The study, conducted in collaboration with a leading Japanese academic research team, revealed a novel mechanism by MN-002, the primary metabolite of MN-001, enhances cholesterol efflux in macrophages through upregulation of ABCA1 and ABCG1 transporters. This mechanism is critical because cholesterol efflux is the first step in Reverse Cholesterol Transport (RCT)—the body's natural process
- PRMediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory AdvisorLA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Breder, MD, PhD, is a distinguished physician-scientist and regulatory expert with over two decades of experience across the U.S. Food and Drug Administration (FDA) and major pharmaceutical compa
- SECSEC Form 10-Q filed by Medicinova Inc10-Q - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough AwardsLA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that the company has been selected as a winner of the "Contract Research and Development Innovation Award" at the Fifth Annual BioTech Breakthrough Awards. MediciNova earned this recognition for its innovative work advancing MN-166 (ibudilast), the company's lead small molecule drug candidate, currently in development for several neurological diseases, including amyotrophic lateral sclerosis (ALS), one of the fatal neurodegenerative diseases. MN-166 is designed t
MNOV FAQ
6 questionsWhat does Medicinova Inc do?
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221...Where does MNOV stock trade?
Medicinova Inc (MNOV) is listed on NASDAQ.What sector and industry is MNOV in?
Medicinova Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MNOV?
Medicinova Inc has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1000.00 price target on 2026-03-16. Recent price targets cluster around $1000.00.What companies are similar to MNOV?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MNOV side-by-side with any of them on Quantisnow.How can I track MNOV on Quantisnow?
Quantisnow aggregates Medicinova Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNOV to receive live email and push alerts on every new disclosure.